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Alzheimer's Disease and Down's Syndrom e:
An Overview
Dr. Devanshu Desai, M.B.B.S.

The association between Al zheimer's Disea se and Do wn 's Syndrome is well
recognized through clinical observations and genetic stu d ies. However, the
exact nature and the implications of this link is fa r fro m clear as yet. The
cha lle nge of diagnosis, genetics and the differences in clinical present atio ns of
Alzheimer's Disease in relation to the Down's Syndrome are reviewed here.
Promising areas of research are pointed out and impo rtance of relevant family
history is emphasized. A current knowledge in th e su bject t hroug h various
stu d ies is presented.

INTRODUCTION

The association between Down's Syndrome [DS] and Alzheimer's Disease
[AD] has been well recognized for some time now. Senile plaq ues were first
described in DS brains in 1921 by Struwe. In 1948 J ervis described clinical
deterioration and Alzheimer's neuropathology in DS. It is also suggested now
that this association is two-sided! On o ne hand individ ua ls with DS tend to
develop AD at so m e point in th eir lives ifthey survive long enough (1-5). On the
other hand, there have been some reports of h igh er t ha n expected frequencies
of DS in families with AD (5, 6). Mo r e rece ntly, a gene defect associated with the
" fam ilial Alzheimer's Disease" (FA D) has been mapped to chromosome 21 , a
chromosome related to DS (7,8) . Although some of th ese find ings are disputed,
it is worthwhile to review current knowledge in th e relati onsh ip between these
two conditions, while awaiting further information abo ut cli nicopatho logical
and genetic association between them.
T h is overview describes each of these two conditions briefl y in relation to
th e other and then examines th e association and th e implica tio ns of th is association between them.
In this overview , th e term A D is used to refer to ind ividuals with a
prov isional diagnosis of Primary Degenerative Dementia of Alzheimer's type.
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Alzheimer's Disease-Diagnostic Accuracy

Primary Degenerative Dementia-Alzheimer's type, is a neuropatholog ical
diagnosis. It is the commonest cause of dementia in the general populatio n an d is
frequently encountered entity in clinical settings in individuals presenting wit h
symptoms of dementia. AD remains mainly a diagnosis of exclusio n . A ntemortem diagnostic accuracy depends on variety of factors , including patient selection, diagnostic criteria and assessment methods. The postmortem hi stologica l
verification of the diagnosis is therefore the gold standard (9).
AD in persons with a normal karyotype usually begins with learnin g and
memory deficits, and slowly progresses to involve all the aspects of intellectual
activity including judgement, calculation and language (10). In the early stages,
psychometric assessment indicates more profound impairment of ideomo tor
performance than language (10). Dalton et al (11) reported that memor y loss,
depression and disorientation were the most frequently reported early sym ptoms of AD in patients with a normal karyotype. In comparison, th ese are th e
least frequently reported symptoms in DS individuals who developed AD (1 1).
There have been several reports systematically describing fun ctional and
clinical disturbances in AD in the general population and the reader is advised
here to refer to the relevant literature for a detailed description.
The differential diagnosis of dementia has remained a challenge. There are
several assessment methods now available which are reasonably sensiti ve and
specific in differentiating causes of dementia. Many in vestigators have used
behavioral observations (12), while the others have used sophisticated neurodiagnostic tools including Computed Tomography (CT), Positron Emission T omography (PET), Single Photon Emission Computed Tomography (SPECT), Xe non
inhalation, Electroencephalography (EEG), Evoked potentials and co mb ina tions
of these for the etiologic diagnosis of dementia (9). However because o f factors
such as cost/benefit ratio, sensitivity, specificity and accessibil it y, these meth od s
have remained research tools at large. At present, there is no 'go ld standard'
criterion or test for the determination of etiology of dementia in clinical settings.
The etiologic diagnosis of dementia is critical because some o f th e o ther ca uses
are treatable or at least controllable to some extent.
As mentioned earlier, diagnostic accuracy of AD depends on a variety of
factors. Tiemay et al (13) reported that accuracy varied between 81 % and 88 % in
clinical settings. A retrospective review b y Bolier et a l ( 14) and th e report o f
Joachin et al (15) suggest that elaborate clinical investigations m ay no t enhance
diagnostic accuracy. In research settings the diagnostic acc uracy may exceed
90 % (9). Morris et al (16) reported 100% accuracy in a sel ected sa mple of 31
cases with strict inclusion and exclusion criteria with out any reference to
neuropsychological test performance. These findings app ly to th e general population with normal or unknown karyotype, where, in ab sence of a 'gold standard' , the selection of a sample is extremely difficult. T he issue of d iagnost ic
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accuracy is much more difficult, particularly in the early stage of AD, in t he
individuals with DS.
Genetics ofAD

A genetic basis for some cases of AD was first suggested in 19 33 (17). There
are case reports describing ' fa m ilial Alzheimer's disease' [FA D] (18, 19), characterized by early onset dementia. Brietner et al in recent studies (20, 2 1) indicated
that the majority of these cases are inherited as an autosomal dominant mutation. In a more recent study (22) they reported a striking increase in cum ula tive
incidence of AD-like illness among the first degree relati ves of AD probands.
Bird et al (23) noted significant phenotypic heterogeneity in 180 deme nt ed
individuals from 24 kindreds. They noted clinical and neuropathological d ifferences among families with AD. They raised questions whether th ere is more
than one type of AD, even among FAD patients and whether th e phen otypic
heterogeneity represents a genetic heterogeneity or is merely an epiphe nomenon. St. George Hyslop et al (8) recently reported FAD linked to two chromosome 21 q21 loci in four families. One of these two markers is link ed to the
amyloid B gene. Thus the q21 region of the long arm of chromosom e 2 1 seems
to be of particular relevance to AD. Some groups of pedigrees have been
assembled in which autopsy determined AD appears to be inherited as an
autosomal dominant trait (24). However, the findings of genetic linkage were
disputed by Schellenberg et al (24). They found no evidence of linkage bet ween
FAD and chromosome 21 markers, including the am yloid B gene. T hey obtained strong evidence for genetic heterogeneity when they compar ed their
study group to St. George Hyslop et aI's group. In this study, most of the
evidence for exclusion of genetic linkage came from presenile onset families ,
although the age of onset was higher than that in St. George H yslop et aI's
group. They mentioned the possibility that the gene in chromosome 2 1 may
account only for very early onset FAD.
There also are some other results suggesting genetic invol ve ment in AD .
From Heston et aI's careful genetic study (3) of 125 families, so me relatives of
younger probands from autopsy proven AD appear to be at increased risk of
Down's syndrome, of myeloproliferative disorders and immune system d isorders. Kallmann's (25) investigation oftwin pairs suggested monozygotic co ncordance in AD. All these evidences suggest a genetic component in at least some
cases of AD. The exact nature of such genetic contribution is yet to be kno wn .
Down's Syndrome

Ever since the classical description of 'Mongolism ' by Langdon Down in
1866, this has remained the most discussed and the most investigated syndrome
in the field of mental retardation. The presence of an extra small ch r omoso me
was reported by Lejeune in 1959, and was later identified as ch romosome 21 .

78

JEFFERSON JO UR NAL O F PSYCH IAT RY

These patients present with a var iety of physical characte ris tics and clini cal
problems.
Onl y two decades ago , very few DS individuals survived through midad u lthood because of associated congenital heart di sea se , recurre nt infectio ns
and a variety of other problems. With advancing health care an d medical
te chnology, more and more of these individuals surv ive until 40 years and
be yond. According to recent data by Baird and Sado vn ick (33), 80 % of DS
patients without congenital heart disease survive pa st th e age of 30 years. Mo re
than 50 % of their DS patients reached their 50 's and 13. 5 % reached age 68.
These observations are significant in relation to the development of AD neuropathology in these individuals.
Studies have shown a higher than average incidence of h ypoth yr o id ism
(34-37), and at least average incidence, if not higher, of depression (38) in DS.
Hypothyroidism in DS is expressed usually as abnormality in o ne or mo re
thyroid function tests whereas clinically, most of these individuals are asymptomatic. Hollingworth et al (39) compared T4, T3 and TSH levels in 60 DS patients
to controls and did not find a significant difference. Howe ver, six DS patients
had goiter and seven had exophthalmos without goiter. Man i (40) studied 55
adult hospital DS patients; almost all of them were 40 yea rs or over. H e found a
high frequency of clinical features suggesting h ypothyro idi sm. H e recommended screening th yroid function in all DS individuals over 40.
In spite of the lack of evidence pointing to specific ca uses of hypoth yroidism , so m e ha ve suggested autoimmunity as an etiologic facto r fo r underactivity of the th yroid gland (40) . Most of these stu d ies fou nd antibo dies to thyroid
tissue in DS patients. Increased rates of lymphocytic leukemia and ot her malignancie s and a higher incidence of viral and bacterial infectio ns have also been
reported (41-43). A higher incidence of congenital hypothyr o id ism had also
been reported (44).
In 1981 , Harrell et al (45) reported benefici al effects of vita m ins, minerals
and th yroid compound in improving intellectual fu nction ing in pe rsons wit h DS.
They did not evaluate th yroid function prior to therapy. Subsequent att e mpts to
replicate these results with vitamin and mineral therapy were un successful (46).
Tiurosh and Toub et al (47), in a double blind cross-o ver drug-placebo trial,
stu d ied a small sample to assess the efficacy of short term th yr oid su pplement in
DS individuals with low borderline th yroid fun ction. They fo und no significant
gains with thyroid supplement. Replication of similar results o n a larger sample
with more attention towards symptoms of dementia is needed to clarify the
indications for thyroid supplement in DS individuals.
A high prevalence of psychiatric disorders in th e mentall y retarded, including those with DS, has been reported (4 8). Several case reports of major
depression in DS patients hav e been published (49 ,50), a lthoug h th ere have been
so me unusual presentations and disagr eements in th e d iagnosis of affective
di sorders in moderate to se vere retardation. Estimates of th e preva lence of
depression in DS are not availabl e at present. Consid ering men ta lly re ta rded of
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all th e different etio logies as a single group, it seems like ly that affective
di so rders are at least as common in th ese indi viduals as in general population
(38). This is particularly significant in DS pati ent over age of 40, sinc e it
complicates the detection of early AD .
Alzheimer's Disease in Down's Syndrome

Alongside the clinical obser vations and genetic stu d ies in AD patients, there
ar e several reports on DS individuals that sugges t a str iking association between
these two conditions. However, th e nature and th e clinical and genetic impl ications of this association remains elusive. Neuropathologica l cha nges of AD in
brains of DS individuals have been r eported for more than 50 years now. Since
Struwe 's report in 1929, it is well recognized fr om severa l stu d ies t hat virtually
all DS individuals 37 years or over develop AD neuropathology, na mely, extensive neurofibrillatory degeneration and senile plaques, throughout wides pread
regions of neocortex (26,27); Certain dermatoglyphic patterns are co mmon in
DS patients (28,29,30), and the extension of th ese stu d ies to their parents
showed unusual combinations of dermatoglyphic patterns in pare nt s, pa rticularly in a parent in whom non-disjunction occurred (31) . Dermato glyph ic changes
sim ilar to DS were also observed in AD by Weinrab wh o repo rted a high
frequency of ulnar loops on fingertips of both AD and DS patients (32). These
and other evidences are becoming clearer as the surv ival of DS individuals is
prolonged.
Clinically, some investigators have observed difference s in sympto ms of AD
in DS patients and in general population. Dalton et al (11) reviewed 35 DS cases
from several case reports. They examined 18 descriptive terms of fun ct ion al an d
clinical features in these cases excluding language based di sturban ces. They
found that the most frequently reported c1inico-functional ex p ression in these
cases was clinical seizures (87.8 %); followed by personality changes (45 .5 %) and
focal neurological signs (45.5 %). The most frequentl y reported sym ptoms in
patients with AD in general population-i.e . memory loss, depressio n and
disorientation-were the least frequently reported in persons with A D in DS.
Besides, differences were noted in self help skills and level of ac tivity in th ese two
groups with AD . Although such comparison between unmatch ed groups and
variable interpretations of retrospective clinical records can provide som e direction for further research , it serves little in clarifying the confusion regarding the
natural history of AD in DS.
Only one prospective study on AD in DS is reported in lit erature (5 1). In
this study of 49 clinically demented DS indi viduals ove r age 35 followed
longitudinally, the average age of dementia onset was 54.2 + 6.1 years, which is
much earlier than AD in the general population. In 23 patien ts who died, the
average duration was 4.6 + 3.2 years with no sign ificant difference betwee n the
sexes. This study was also able to delineate seve ra l features of A D in the ir DS
patients. (i) The first signs of dementia in DS-changes in perso nal ity such as
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irritability and emotional labil ity in most cases in th eir study populationcorrelate wit h the lat e features of AD in general populati on . (ii) There is a latent
period of 2 to 3 decades between the time of onset of neuropat ho logica l changes
and clinical symptoms. (iii) Prevalence of dementia increases wit h age. (iv) There
is higher incidence of se izu res in th ese individuals as compared to AD patients in
general population . (v) T wenty percent of DS outpatients with deme nt ia a lso
developed Parkinson's dis ea se.
DISCUSSION

The available information about the association between A D and DS raises
many questions and hypotheses, most of which still remain unanswered . The
differences noted in clinical features of AD in DS and in persons with normal
karyotype poses a question if there is a different etiology and pathogen esis of A D
in these two groups (11). This questions the significance of pathological changes
and the clinicopathological correlation in AD. The issue is further co mplicated
by findings of changes identical to AD in many elderly brains in absence of
clinical symptoms. Interestingly enough, there are at lea st two case reports of DS
patients-one 49 year s and the other 47 years of age-who showed no neuropathology of AD in brain on autopsy (52,53). The prevalence of AD increases with
age in DS as well as general population and it is assumed that th e agin g process
begins early and progresses rapidly in DS individuals (54 ). These obse rvations
support Gowers' concept with the implication that AD represents merely a
precocious aging of central nervous system (55). If so, one can assume th at every
individual who lives long enough will develop AD at some point. It may be
possible that the symptoms appear only when brain changes are extensive
enough or when they involve certain brain areas, such as hippocampus.
However, from epidemiological evidence and clinical observations, there is
little doubt that a disease process is involved in AD. Besides th e issue of ca usal
factors it also remains to be seen if there are separate factors that contro l th e age
of onset in AD .
Almost all DS individuals show AD neuropathology at so me point , and up to
85 % of these-presumably all if they lived long enough-develop AD (5 1).
Theoretically it seems possible to detect AD in its early phase and to delineat e its
natural history in this cohort. In that case, the idea of detecting a " he ra ld sign"
that predicts or signals the onset of clinical AD appears promising. An indi vid ual
sign which increases in prevalence with advancing age ma y need careful scrutiny.
Examples of such signs would include primitive reflexes, face -hand te st etc., of
course, this would require several detailed longitudinal observati ons.
As mentioned earlier, there are strong indications of a genetic link betwee n
AD and DS. Although a chromosomal abnormality in AD needs furth er confirmation, if present, it could be of tremendous help in screen ing potential pare nt s
with high risk pregnancies. For clinicians, it would be important to include
spec ific questions in obtaining the famil y history of individuals with these
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con di t io n s. In co n cl us io n, th ere is no d oubt about th e r el a ti o n sh ip between AD
a n d DS , but t her e are se ve r a l unanswered que stio n s regarding the nature of this
relationship. The issu es of o r ig in , pathogenesis a n d th e natural history of
dementia in DS awaits furth er prospective stud ies. Th e g roup of DS individuals
se e m s a readily available " id ea l" co h o r t because of th eir a lmost certain ly known
outcome. Obviously, this will be a promising area of r ese arch in the field of
ps ychiatry and the study of mental retardation .
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